Blisibimod
Sponsors
Anthera Pharmaceuticals
Conditions
Granulomatosis With PolyangiitisIdiopathic Thrombocytopenic PurpuraIgA NephropathyImmune Thrombocytopenic PurpuraMicroscopic PolyangiitisSystemic Lupus Erythematosus
Phase 2
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
WithdrawnNCT01598857
Start: 2014-12-31Updated: 2015-07-30
MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP
WithdrawnNCT01609452
Start: 2015-12-31Updated: 2015-07-30
BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
CompletedNCT02062684
Start: 2013-06-30End: 2017-06-30Updated: 2017-09-18
Phase 3
CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
CompletedNCT01395745
Start: 2013-02-28End: 2016-10-31Updated: 2017-02-03
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
WithdrawnNCT02052219
Start: 2014-10-31End: 2021-10-31Updated: 2015-07-30
CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
WithdrawnNCT02074020
Start: 2015-12-31Updated: 2015-08-13
CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
TerminatedNCT02514967
Start: 2016-06-30End: 2017-02-28Updated: 2017-05-23